Abstract 163P
Background
GIST is not common in AYA patients and the data on AYA GISTs are limited. In our institution, the typical adult GIST patient is male (52.9%), with mutations in KIT (53.6%) or PDGFR (4.2%), has gastric as the primary location (54.4%), and a five-year overall survival (OS) of 51%. We studied the clinical and genetic characteristics and prognoses of AYA GISTs.
Methods
All GIST patients diagnosed between the ages of 16-39 at National Cancer Centre Singapore from 1 January 2002 to 31 December 2018 were included. We retrospectively studied their clinico-molecular characteristics and outcomes.
Results
41 AYA GIST patients were seen with a median age of 34 years old. 25 patients (61.0%) were male. 27 patients (65.9%) were Chinese. 9 (22.0%) had metastatic disease at diagnosis. The tumours were primarily in the jejunum/ileum (41.5%, n=17) or stomach (34.1%, n=14). 25 patients (61.0%) had tumor mutation testing performed. Of these, 19 (76%) had KIT and one (4%) had PDFGRA. 5 (20%) were KIT/PDGFR wildtype. Of those with KIT mutations, 17 (89.5%) were in exon 11, while 2 (10.5%) were in exon 9. The PDGFRA mutation was in exon 18. No data is available on genetic syndromes. 24 patients (58.4%) received curative-intent treatment with 3 (12.5%) subsequently had local recurrences. 14 (58.3%) received imatinib in a neoadjuvant/adjuvant setting. 17 patients (41.5%) received palliative-intent treatment with 13 (76.4%) receiving palliative imatinib. 9 (52.9%) had Sunitinib after progression. The median follow-up was 48 months (0-165). 6 patients (14.6%) had demised. Median OS for all patients was 162.0 months (95% CI: 80.8– 243.2) with no significant differences with regards to age (p=0.07), gender (p=0.91), presence of a sensitising mutation (KIT Exon 9 and 11) (p=0.26), and treatment intent (p=0.2). A significant OS difference was found between patients undergoing curative or palliative intent (162.0 vs 65.0 months, p=0.001) and in patients with different primary tumor location (p=0.029). Out of the 6 patients with uncommon primary tumor locations, 3 had demised.
Conclusions
AYA GISTs differ from adult GIST. In our series, 61.0% had tumor mutation analysis performed. AYA GIST also has a higher rate of small intestine primary. Further studies are needed to evaluate the low mutation and genetic testing and clinico-molecular differences to better understand how these affect outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session